A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with ...
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback